Bristol-Myers Squibb Company (BMY)
| Market Cap | 94.15B |
| Revenue (ttm) | 48.03B |
| Net Income (ttm) | 6.04B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.97 |
| PE Ratio | 15.57 |
| Forward PE | 7.42 |
| Dividend | $2.48 (5.36%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 14,136,268 |
| Open | 46.17 |
| Previous Close | 45.94 |
| Day's Range | 45.52 - 46.99 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.31 |
| Analysts | Hold |
| Price Target | 55.64 (+20.3%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $55.64, which is an increase of 20.30% from the latest price.
News
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity. BMY's pipeline and recent acquisitions are unlikely to offset revenue...
Bristol Myers, Sanofi sued by Texas over Plavix
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for...
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers.
Why Bristol-Myers Squibb Remains Undervalued In 2025
Bristol-Myers Squibb remains my favorite, almost the only Big Pharma stock that hasn't left the accumulation zone. Sales of its "gem" in the cardiovascular franchise, Camzyos, were $296 million in Q3,...
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers.
Why Are These 4 Dividend Stocks Still Trading At A Deep Discount?
Will the stock market finish the year higher or lower?
S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls
Shares of a delivery giant surged Friday on a new partnership, while a pharmaceutical firm came under pressure after it halted a trial of a key heart treatment.
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy
Bristol Myers Squibb & Co. (NYSE: BMY), in collaboration with Johnson & Johnson (NYSE: JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safet...
Bristol Myers, J&J halt heart drug trial after interim review
Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study...
Update on Phase 3 Librexia ACS Trial
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Update on Phase 3 Librexia ACS Trial.
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squi...
Final Trade: UNH, OIH, AMD, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes.
Bristol Myers reaches $239 million settlement over psoriasis, MS drugs
Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now kno...
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors
PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a cli...
Bristol-Myers Squibb: Way Too Cheap At 7x P/E
Bristol-Myers Squibb is a compelling value and income opportunity, trading near 52-week lows with a 5.4% dividend yield and low forward P/E. BMY's growth portfolio, led by Opdivo, Reblozyl, and Breyan...
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth
Bristol-Myers Squibb (BMY) remains a "Strong Buy" rating, driven by robust growth in its hematology and cardiovascular portfolios, especially Breyanzi and Camzyos. Breyanzi and Reblozyl achieved impre...
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings ...
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions.
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes.